Drug Profile
SYHA 136
Alternative Names: SYHA-136Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Venous thrombosis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Venous-thrombosis(Prevention) in China (PO, Tablet)
- 20 Nov 2019 Phase-I clinical trials in Venous thrombosis (Prevention) in China (PO)
- 01 Aug 2019 CSPC ZhongQi Pharmaceutical Technology plans a phase I trial for Venous thrombosis (In Volunteers, Prevention) (PO, Tablet) (NCT04036656)